ACADIA Pharmaceuticals Inc Discuss The Exclusive Worldwide Licensing Of Trofinetide Call Transcript - Thomson StreetEvents

ACADIA Pharmaceuticals Inc Discuss The Exclusive Worldwide Licensing Of Trofinetide Call Transcript

ACADIA Pharmaceuticals Inc Discuss The Exclusive Worldwide Licensing Of Trofinetide Call Transcript - Thomson StreetEvents
ACADIA Pharmaceuticals Inc Discuss The Exclusive Worldwide Licensing Of Trofinetide Call Transcript
Published Jul 13, 2023
Published Jul 13, 2023
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ACAD.OQ conference call or presentation 13-Jul-23 8:30pm GMT

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
ACADIA Pharmaceuticals Inc
Ticker
ACAD.OQ
Time
8:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Steve and team, congratulations on the updates all around. Steve, just a follow-up on your commentary and Kathie's on the regulatory proceedings outside of the U.S. I'm just curious if you could comment on maybe the calculus involved with respect to the infrastructure and the resources required for you and the team to go ex U.S., I would imagine that there are some considerations on broadening that infrastructure given the sort of new grounds for ACADIA. So any commentary you have on how that would look, would be great. And then secondly, just with respect to the priority review voucher, what are the latest plans there seeing 1 transaction more recently in this space. Just curious how you're handling of a sale versus a hold on what the latest is on the PRV. Congratulations again. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JULY 13, 2023 / 8:30PM, ACAD.OQ - ACADIA Pharmaceuticals Inc Discuss The Exclusive Worldwide Licensing Of Trofinetide Call

Table Of Contents

ACADIA Pharmaceuticals Inc Q3 2023 Earnings Call Transcript – 2023-11-02 – US$ 54.00 – Edited Transcript of ACAD.OQ earnings conference call or presentation 2-Nov-23 8:30pm GMT

ACADIA Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference Transcript – 2023-09-26 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 26-Sep-23 3:30pm GMT

ACADIA Pharmaceuticals Inc at TD Cowen Novel Mechanisms in Neuropsychiatry Summit Transcript – 2023-09-20 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 20-Sep-23 9:00pm GMT

ACADIA Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript – 2023-09-12 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 12-Sep-23 4:15pm GMT

ACADIA Pharmaceuticals Inc Q2 2023 Earnings Call Transcript – 2023-08-02 – US$ 54.00 – Edited Transcript of ACAD.OQ earnings conference call or presentation 2-Aug-23 8:30pm GMT

ACADIA Pharmaceuticals Inc to Announce Phase 3 Development Candidate ACP-101 Call Transcript – 2023-06-13 – US$ 54.00 – Edited Transcript of ACAD.OQ conference call or presentation 13-Jun-23 9:00pm GMT

ACADIA Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript – 2023-05-10 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 10-May-23 6:20pm GMT

ACADIA Pharmaceuticals Inc Q1 2023 Earnings Call Transcript – 2023-05-08 – US$ 54.00 – Edited Transcript of ACAD.OQ earnings conference call or presentation 8-May-23 8:30pm GMT

ACADIA Pharmaceuticals Inc Approval Call Transcript – 2023-03-13 – US$ 54.00 – Edited Transcript of ACAD.OQ corporate analyst meeting</ 13-Mar-23 12:30pm GMT

ACADIA Pharmaceuticals Inc Q4 2022 Earnings Call Transcript – 2023-02-27 – US$ 54.00 – Edited Transcript of ACAD.OQ earnings conference call or presentation 27-Feb-23 9:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "ACADIA Pharmaceuticals Inc Discuss The Exclusive Worldwide Licensing Of Trofinetide Call Transcript" Jul 13, 2023. Alacra Store. May 12, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/ACADIA-Pharmaceuticals-Inc-Discuss-The-Exclusive-Worldwide-Licensing-Of-Trofinetide-Call-T15660362>
  
APA:
Thomson StreetEvents. (2023). ACADIA Pharmaceuticals Inc Discuss The Exclusive Worldwide Licensing Of Trofinetide Call Transcript Jul 13, 2023. New York, NY: Alacra Store. Retrieved May 12, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/ACADIA-Pharmaceuticals-Inc-Discuss-The-Exclusive-Worldwide-Licensing-Of-Trofinetide-Call-T15660362>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.